
    
      This is a first in human phase 1 multicenter open label study to evaluate the safety and
      tolerability of AMG 224 in subjects with relapsed or refractory multiple myeloma. The study
      will be conducted in 2 parts. Part 1 is the dose-exploration and part 2 is the
      dose-expansion. Study medication will be administered once every 3 weeks by IV.
    
  